Description

Simple

Clinical

Overview

Viomycin is a tuberactinomycin antibiotic that was used to treat Mycobacterium tuberculosis until it was replaced by the less toxic capreomycin. These drugs bind RNA in bacterial ribosomes and inhibit protein synthesis. Viomycin was derived from the actinomycete _Streptomyces puniceus_.

Pharmacology

Indication

Viomycin is an essential component in the drug cocktail currently used to fight infections of Mycobacterium tuberculosis.

Pharmacodynamic

Information currently not available.

Mechanism of action

Viomycin binds to a site on the ribosome which lies at the interface between helix 44 of the small ribosomal subunit and helix 69 of the large ribosomal subunit. The structures of this complexes suggest that the viomycin inhibits translocation by stabilizing the tRNA in the A site in the pretransloc... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Viomycin
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The risk or severity of bleeding can be increased when Viomycin is combined with (R)-warfarin.
(S)-Warfarin
The risk or severity of bleeding can be increased when Viomycin is combined with (S)-Warfarin.
4-hydroxycoumarin
The risk or severity of bleeding can be increased when Viomycin is combined with 4-hydroxycoumarin.
Acenocoumarol
The risk or severity of bleeding can be increased when Viomycin is combined with Acenocoumarol.
Alcuronium
The therapeutic efficacy of Alcuronium can be increased when used in combination with Viomycin.
Apramycin
The risk or severity of neuromuscular blockade can be increased when Apramycin is combined with Viomycin.
Arbekacin
The risk or severity of neuromuscular blockade can be increased when Arbekacin is combined with Viomycin.
Atracurium
The therapeutic efficacy of Atracurium can be increased when used in combination with Viomycin.
Atracurium besylate
The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Viomycin.
BCG vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Viomycin.
Bekanamycin
The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Bekanamycin.
Botulinum toxin type A
The risk or severity of adverse effects can be increased when Viomycin is combined with Botulinum toxin type A.
Botulinum Toxin Type B
The risk or severity of adverse effects can be increased when Viomycin is combined with Botulinum Toxin Type B.
Capreomycin
The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Viomycin.
Chloroquine
The risk or severity of neuromuscular blockade can be increased when Chloroquine is combined with Viomycin.
Cisatracurium
The therapeutic efficacy of Cisatracurium can be increased when used in combination with Viomycin.
Clindamycin
The risk or severity of neuromuscular blockade can be increased when Clindamycin is combined with Viomycin.
Clomocycline
The risk or severity of neuromuscular blockade can be increased when Clomocycline is combined with Viomycin.
Clorindione
The risk or severity of bleeding can be increased when Viomycin is combined with Clorindione.
Colistimethate
The risk or severity of neuromuscular blockade can be increased when Colistimethate is combined with Viomycin.
1 References
  1. 1 . Noda T, Take T, Nagata A, Wakamiya T, Shiba T: Chemical studies on tuberactinomycin. 3. The chemical structure of viomycin (tuberactinomycin B). J Antibiot (Tokyo). 1972 Jul;25(7):427-8.PubMed: 4350196